Nippon Express to provide global pharmaceutical supply networks
The company is already constructing a digital platform for the pharmaceutical industry that will utilize IoT devices and blockchain technology to link temperature control and other logistics information end-to-end.
Nippon Express is in the process of developing pharmaceutical supply chain networks that meet both hardware and software requirements for Good Distribution Practices (GDP) to enable safer and more secure supply of pharmaceuticals.
In view of the globalization of pharmaceutical supply chains, the company will also be setting up GDP-compliant business locations in major markets worldwide to enhance its supply networks on a global level.
Nippon Express is currently setting up pharmaceutical-specific facilities in East Japan, West Japan, Kyushu and Toyama to complement the 'medical hubs' of Narita International Airport and Kansai International Airport, which have long been involved in the import/export of raw materials and finished products.
These facilities will be equipped to handle GDP-compliant quality control and business continuity plans pertaining to pharmaceutical supply, and platforms will be constructed to allow for joint warehouse storage and transport, operations heretofore carried out on an individual customer basis, to cope with the shortages of truck drivers stemming from the round use of vehicles, and to achieve greater operational efficiency. These facilities will go into service in February 2021.
More specifically, the company is building GDP-compliant CFS at key pharmaceutical business locations overseas. It has already opened GDP-certified CFS in London and Milan, which both host clusters of manufacturers of new drugs, as well as in India, where generics are driving robust market growth; in the US, GDP certification was acquired in Chicago.
In addition to enhancing business locations in Europe and the US, Nippon Express is planning to obtain GDP certification in Asian countries where medical services are becoming more widely accessible.
Furthermore, Nippon Express will be looking to employ the digital technologies of IoT (Internet of Things) and blockchain to track logistics information end-to-end, to optimize supply chains for the industry as a whole via a data-driven approach that offers traceability and increased operational efficiency.
To ensure it has in place the extensive expertise and strict quality control required for pharmaceutical logistics, Nippon Express created a Pharmaceuticals Business Division and a Pharmaceuticals Logistics Quality Assurance Office in July 2020 to establish uniform group-wide standards on, for example, operational frameworks, human resource development, quality assurance regimes.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance